Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurodynamics of DMT and Harmine in Healthy Subjects
NCT04716335Phase 1Completed
- Sponsor
- Psychiatrische Universitätsklinik Zürich
- Start
- Dec 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing Harmine + DMT, Harmine + Placebo and Placebo + Placebo (3 arms). Primary endpoints: Social Value Orientation, Charity Donation Frank Task and 4 more. Started Dec 2020; status: completed.
02
Drugs
DMTharmine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04716335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04716335.